Health
J&J COVID-19 vaccine is 72% effective in the U.S., and 66% overall in large trial – Reuters
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will…
(Reuters) – Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the coronavirus.
FILE PHOTO: A vial and sryinge are seen in front of a displayed Johnson&Johnson logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from…
-
Noosa News13 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business17 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business13 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General23 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts